NCT06162533 - Severe Acute Respiratory Syndrome Coronavirus 2 Re-Infection Risk and Vaccine Efficacy in Austria | Biotech Hunter

Enrollment

9,090,868

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Vaccination against SARS-CoV-2

Interventions are either a vaccination against SARS-CoV-2 or an infection with SARS-CoV-2

Trial Locations (3)

Medical University of Graz, Graz

Medical University of Innsbruck, Innsbruck

Austrian Agency for Health and Food Safety, Vienna